Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Frequently asked questions
What sector does Evaxion Biotech AS (EVAX) operate in?
Evaxion Biotech AS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Evaxion Biotech AS (EVAX) current stock price?
As of the latest data, Evaxion Biotech AS stock price is $3.27, with a previous close of $3.18. Evaxion Biotech AS gained $0.09 in the last trading session, representing a 2.83% increase.
What is Evaxion Biotech AS (EVAX) current market capitalization?
Evaxion Biotech AS market cap is approximately 27.27 million.
What is Evaxion Biotech AS (EVAX) Earnings Per Share (EPS)?
The trailing EPS is -$1.01, and the forward EPS is $0.04.
What is Evaxion Biotech AS (EVAX) EBITDA?
Evaxion Biotech AS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.51 million.
Does Evaxion Biotech AS (EVAX) pay dividends?
No. Evaxion Biotech AS does not pay a dividend.
What is Evaxion Biotech AS (EVAX) beta (volatility) score?
Evaxion Biotech AS has a beta of 0.254, indicating lower volatility than the overall market.
